Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3389899 | 0.92 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2HTTKDM4EKMT2A | |
| SCHEMBL9972731 | 0.83 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2HTTKDM4EKMT2A | |
| SCHEMBL3394366 | 0.78 | PDE4D (0.42) | ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1 | |
| SCHEMBL3612930 | 0.76 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2HTTKDM4EKMT2A | |
| SCHEMBL3762806 | 0.75 | PPARG (0.46) | SMN1; SMN2 | |
| SCHEMBL3757808 | 0.73 | PDE4D (0.45) | — | |
| SCHEMBL3763110 | 0.73 | PDE4D (0.43) | SMN1; SMN2 | |
| SCHEMBL3390635 | 0.72 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2HTTKDM4EKMT2A | |
| SCHEMBL13870626 | 0.72 | HRH3 (0.45) | ALDH1A1SMN1; SMN2HTTKMT2AMEN1 | |
| SCHEMBL3392805 | 0.71 | PDE4D (0.39) | KDM4EKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202513-B2 | Aryl potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-06-19 | — | — | US | disclosed |
| US-8202513-B2 | Aryl potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-06-19 | — | — | US | disclosed |
| US-8202513-B2 | Aryl potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-06-19 | — | — | US | disclosed |
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-11-25 | — | — | US | disclosed |
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-11-25 | — | — | US | disclosed |
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-11-25 | — | — | US | disclosed |
| EP-2197832-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | Bionomics Limited (AU) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009043117-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009043117-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNA3, KCNB1, KCNH3 | ALDH1A1 2549/4885SMN1; SMN2 3554/4885HTT 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.